停药后HBV DNA水平预测核苷(酸)类似物停药后复发:前瞻性停药研究
这项前瞻性研究纳入82例按国际指南停用核苷(酸)类似物的非肝硬化亚洲慢性乙型肝炎患者,随访停药后病毒动力学与临床复发。2年临床复发率在HBeAg阳性患者为31%、HBeAg阴性患者为53%。年龄≤35岁和停药时HBsAg≤200 IU/mL与较低复发率独立相关。停药后HBV DNA升高的水平及持续性有助于预测后续生化复发。
要点
- 停药后2年临床复发率HBeAg阳性31%、HBeAg阴性53%。
- 年龄≤35岁及停药时HBsAg≤200 IU/mL与较低复发率独立相关。
- 停药后HBV DNA升高水平及持续性与后续生化复发风险相关。
核心结论
- 停用核苷(酸)类似物后,年轻患者和停药时HBsAg水平较低者复发率较低。
- 停药后HBV DNA升高的水平及持续性可用于预测后续生化复发,或可指导停药后管理。
研究设计与样本
- 前瞻性研究,纳入82例按国际指南停用核苷(酸)类似物的非肝硬化亚洲慢性乙型肝炎患者。
- 停药后随访,HBV DNA>2000 IU/mL且ALT>2倍正常上限定义为临床复发并再治疗。
主要发现
- 28例发生临床复发,2年复发率HBeAg阳性患者31%、HBeAg阴性患者53%。
临床怎么用
- 停药后应监测HBV DNA水平及其持续性,以评估生化复发风险。
- 对年龄≤35岁或停药时HBsAg≤200 IU/mL者,可预期较低复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal management remains unknown after nucleos(t)ide analogue (NA) discontinuation in patients with chronic hepatitis B (CHB). This prospective study investigated the role of off-treatment viral kinetics in predicting relapse after discontinuation of NA therapy. METHODS: A total of 82 noncirrhotic Asian patients with CHB who discontinued NA therapy according to international guidelines were prospectively followed. Patients with a hepatitis B virus (HBV) DNA level of >2000 IU/mL and an alanine aminotransferase (ALT) level of >2 times the upper limit of normal (clinical relapse) were retreated. RESULTS: Sixty patients were HBV envelope antigen (HBeAg) positive at the start of treatment, and 22 were HBeAg negative. Clinical relapse developed in 28 patients (2-year rates, 31% among HBeAg-positive patients and 53% among HBeAg-negative patients). Age of ≤35 years (hazard ratio [HR], 0.37; P = .026) and end-of-treatment HBsAg level of ≤200 IU/mL (HR, 0.39; P = .078) were independently associated with lower relapse rates. A high risk of biochemical relapse (defined as an ALT level of >2 times the upper limit of normal) was observed if the HBV DNA level was >200000 IU/mL when the level was initially elevated, compared with HBV DNA levels of >2000 to ≤200000 IU/mL (HR, 8.42; P < .001). The risk of biochemical relapse was also high in patients with persistent elevation in the HBV DNA level (confirmed to be >2000 IU/mL within 3 months), compared with the group with transient elevation (HR, 6.87; P < .001). CONCLUSIONS: After NA discontinuation, a lower relapse rate was observed in younger patients and in those with low end-of-treatment HBsAg levels. The level and persistence of off-treatment elevated HBV DNA levels were useful in the prediction of a subsequent biochemical relapse and may thus be used to guide off-treatment management.
引用
- Cao J, Chi H, Yu T, et al. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017. PMID: 28329347. doi:10.1093/infdis/jix025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。